Keith A. Lawson

2.6k total citations · 2 hit papers
28 papers, 629 citations indexed

About

Keith A. Lawson is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Keith A. Lawson has authored 28 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Keith A. Lawson's work include Renal cell carcinoma treatment (8 papers), Renal and related cancers (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Keith A. Lawson is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Renal and related cancers (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Keith A. Lawson collaborates with scholars based in Canada, United States and United Kingdom. Keith A. Lawson's co-authors include Jason Moffat, Thomas M. Norman, Lei S. Qi, Florence M. Chardon, Jonathan S. Weissman, Matthew B. Dong, Jay Shendure, Matthew A. Coelho, Rebecca S. Shapiro and Geoff Stanley and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Keith A. Lawson

24 papers receiving 625 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-content CRISPR screening

2022 276 citations Christoph Bock, Paul Datlinger et al. Nature Reviews Methods Primers profile →
High-content CRISPR screening

2022 170 citations Christoph Bock, Paul Datlinger et al. Nature Reviews Methods Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith A. Lawson Canada	9	448	120	104	72	52	28	629
N. Razavian United States	7	395 0.9×	158 1.3×	59 0.6×	56 0.8×	78 1.5×	27	591
Zhongzheng Cao China	7	746 1.7×	158 1.3×	97 0.9×	33 0.5×	251 4.8×	13	887
Kousuke Tanimoto Japan	18	611 1.4×	86 0.7×	76 0.7×	68 0.9×	307 5.9×	38	890
Bolette Bjerregaard Denmark	14	412 0.9×	188 1.6×	130 1.3×	21 0.3×	59 1.1×	17	682
Seth Sadis United States	9	410 0.9×	65 0.5×	32 0.3×	51 0.7×	87 1.7×	24	640
Subhra Chaudhuri United States	8	392 0.9×	123 1.0×	50 0.5×	42 0.6×	51 1.0×	13	566
Marcia Eisenberg United States	13	181 0.4×	138 1.1×	37 0.4×	92 1.3×	97 1.9×	45	483
Hongzhi Cao China	8	167 0.4×	96 0.8×	91 0.9×	22 0.3×	28 0.5×	17	449
Dean O. Campbell United States	14	334 0.7×	172 1.4×	89 0.9×	22 0.3×	64 1.2×	19	610
François Bachand Canada	13	323 0.7×	42 0.3×	25 0.2×	232 3.2×	32 0.6×	46	736

Countries citing papers authored by Keith A. Lawson

Since Specialization

Citations

This map shows the geographic impact of Keith A. Lawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith A. Lawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith A. Lawson more than expected).

Fields of papers citing papers by Keith A. Lawson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith A. Lawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith A. Lawson. The network helps show where Keith A. Lawson may publish in the future.

Co-authorship network of co-authors of Keith A. Lawson

This figure shows the co-authorship network connecting the top 25 collaborators of Keith A. Lawson. A scholar is included among the top collaborators of Keith A. Lawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith A. Lawson. Keith A. Lawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lawson, Keith A. & W. Marston Linehan. (2024). De-clear cell differentiated renal cell carcinoma — a new therapeutic target. Nature Reviews Urology. 22(2). 73–74.

McAlpine, Kristen, Keith A. Lawson, Olli Saarela, et al.. (2023). Surgeon-level versus hospital-level quality variance in kidney cancer surgery. Urologic Oncology Seminars and Original Investigations. 41(5). 257.e7–257.e17. 2 indexed citations

Deniffel, Dominik, Kristen McAlpine, F Harder, et al.. (2023). Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions. European Radiology. 33(8). 5840–5850. 15 indexed citations

Chen, Bo, Kristen McAlpine, Keith A. Lawson, Antonio Finelli, & Olli Saarela. (2023). Hierarchical causal variance decomposition for institution and provider comparisons in healthcare. Health Services and Outcomes Research Methodology. 23(4). 391–415.

Lawson, Keith A., et al.. (2023). Cystic Renal Masses. Urologic Clinics of North America. 50(2). 227–238. 3 indexed citations

Lawson, Keith A., et al.. (2022). PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma. Nature Reviews Urology. 20(2). 96–115. 34 indexed citations

Bock, Christoph, Paul Datlinger, Florence M. Chardon, et al.. (2022). High-content CRISPR screening. Nature Reviews Methods Primers. 2(1). 276 indexed citations breakdown →

Tatari, Nazanin, Xiaoyu Zhang, Shawn C. Chafe, et al.. (2022). Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors. Frontiers in Immunology. 13. 905768–905768. 9 indexed citations

Li, Tiange, et al.. (2022). Case – An invisible stent. Canadian Urological Association Journal. 17(3). E100–E102.

10.

Palacios, Diego Aguilar, Brigid Wilson, Patrick Michael, et al.. (2021). A Novel Metric for Hospital Quality in Kidney Cancer Surgery: A Veterans Affairs National Health System Validation of Concept. Urology Practice. 9(3). 237–245. 1 indexed citations

11.

Austin, Peter C., et al.. (2020). Constructing inverse probability weights for institutional comparisons in healthcare. Statistics in Medicine. 39(23). 3156–3172. 4 indexed citations

12.

Nayan, Madhur, Olli Saarela, Keith A. Lawson, et al.. (2020). Long-term outcomes after radical or partial nephrectomy for T1a renal cell carcinoma: A population-based study. Canadian Urological Association Journal. 14(12). 392–397. 4 indexed citations

13.

Lawson, Keith A., Robert Abouassaly, Abhinav Khanna, et al.. (2020). Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care. European Urology Oncology. 4(3). 494–497. 2 indexed citations

14.

Lawson, Keith A., Olli Saarela, Zhihui Liu, et al.. (2017). Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. Canadian Urological Association Journal. 11(8). 232–7. 7 indexed citations

15.

Lawson, Keith A., Olli Saarela, Robert Abouassaly, et al.. (2017). The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. European Urology. 72(3). 379–386. 16 indexed citations

16.

Lawson, Keith A., Ahmed Mostafa, Zhong Qiao Shi, et al.. (2016). Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma. Clinical Cancer Research. 22(23). 5839–5850. 31 indexed citations

17.

Mostafa, Ahmed, et al.. (2015). Abstract A12: PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy. Cancer Immunology Research. 3(10_Supplement). A12–A12. 2 indexed citations

18.

Lawson, Keith A., et al.. (2013). Assessment of Antibiotic Prophylaxis Prescribing Patterns for TURP: A Need for Canadian Guidelines?. Canadian Urological Association Journal. 7(7-8). 530–530. 8 indexed citations

19.

Lawson, Keith A. & Don Morris. (2012). Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?. Expert Opinion on Biological Therapy. 12(7). 891–903. 7 indexed citations

20.

Hyndman, M. Eric, Deborah R. Kaye, Nicholas C. Field, et al.. (2012). The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer. Advances in Urology. 2012. 1–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact